A Study of RC48-ADC in Subjects With HER2-Positive Advanced Malignant Solid Tumors

NCT02881138 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumors

Interventions

DRUG: RC48-ADC

Sponsor

RemeGen Co., Ltd.